Previous 10 | Next 10 |
2024-01-31 04:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PITTSBURGH, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, toda...
PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, toda...
2023-12-16 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-11 01:03:08 ET Summary Krystal Biotech's Vyjuvek shows strong early sales for DEB treatment, indicating market acceptance and revenue potential. Financially, Krystal is robust with $598.5M in liquid assets and a low risk of near-term financing needs. Market sentiment i...
If approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for the first time VYJUVEK received Orphan Drug Designation and PRIME designation from the EMA PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ...
2023-11-20 15:03:53 ET More on Krystal Biotech Krystal Biotech Inc. (KRYS) Q3 2023 Earnings Call Transcript Krystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline Enhancement Krystal Biotech Q3 2023 Earnings Preview Cantor starts Krystal Biotech at ove...
2023-11-10 06:55:00 ET It's been a solid year for Krystal Biotech (NASDAQ: KRYS) , a midcap company focusing on developing gene therapies, as it has easily outperformed the market this year. However, zooming out tells an even more impressive story: In the past five years, its shares...
2023-11-09 11:33:03 ET More on Markets Cracks starting to appear in U.S. economy, especially in residential home market – Wells Fargo Morningstar Research calls for the slowing rate of economic growth We are in the early stages of what will be a supercycle in ...
PITTSBURGH, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, anno...
News, Short Squeeze, Breakout and More Instantly...
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U....
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...